Culling The Pipeline: An Analysis Of Biogen's Discontinued Programs
You may also be interested in...
Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?
The big biotech announces Steve Holtzman, former chairman of Infinity, as head of corporate development, with Doug Williams, former CEO of ZymoGenetics stepping in as exec VP of R&D.
Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.
Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.